feedback

Activity Details

Free CME
0.75 AMA PRA Category 1 Credit(s)
Released: June 19, 2019
Expires: June 19, 2020
0.75 hour(s) to complete

Provided By

Target Audience

This educational activity is directed toward lipidologists, cardiologists, nurse practitioners, physician assistants, and other specialty healthcare providers (HCPs) interested in the treatment of hypercholesterolemia.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Summarize the findings from CV outcomes studies of PCSK9i
  • Identify specific patient populations that would benefit from LDL-C lowering utilizing PCSK9i therapies
  • Apply the guidance from the latest clinical recommendations for the use of PCSK9i
  • Implement strategies to overcome common obstacles and potential solutions to increase patient access to PCSK9i

Activity Description

This program is designed to summarize the latest clinical trial evidence regarding PCSK9i, as well as the latest clinical recommendations for the use of PCSK9i. It will include a discussion of common barriers to PCSK9i prescription approval and recommend potential solutions to overcome these obstacles and improve patient access to PCSK9i.

Faculty

James A. Underberg, MS, MD, FACP, FNLA
Clinical Assistant Professor of Medicine
NYU School of Medicine
NYU Center for Prevention of Cardiovascular Disease
Director Bellevue Hospital Lipid Clinic
New York, New York


Kevin C. Maki, PhD
Adjunct Faculty in Biostatistics and Epidemiology
DePaul University
Chief Scientist
Midwest Biomedical Research/Center for Metabolic & Cardiovascular Health
Chicago, Illinois


Conflict of Interest Policy/Disclosure Statement

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

James A. Underberg, MS, MD, FACP, FNLA
Consulting Fees: Amarin, Amgen
Fees for non-CME Services: Amarin, Alexeron, Amgen, Regeneron, Sanofi
Contracted Research: Aegerion, Pfizer, Sanofi
Other (Steering Committee Member): Aegerion Lower Registry Trial

Kevin C. Maki, PhD
Consulting Fees: Abbott, Amegen, Corvidia Therapeutics, Matinas BioPharma, Pharmavite
Contracted Research: Abbott, Amgen
Ownership Interest: Amgen, Amarin

The Integrity CE planners/managers have nothing to disclose.

Accreditation Statement

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving CME credit for this activity. During the period of June 19, 2019 through June 19, 2020 participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 75% or better.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. and Amgen do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Contact Information for Questions About the Activity

For information about the ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or via email at information@integrityce.com.

Statement of Commercial Support

This activity is supported by educational funding provided by Amgen.

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Start Activity

Select your specialty

You must select a specialty

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.